HDFC Pharma & Healthcare IDCW Reinvest Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹100

HDFC Pharma & Healthcare IDCW Reinvest Direct Plan

NAV
₹17.3470
+0.65%
(5 Feb)
AUM
1,984 Cr
TER
0.94%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Total Expense Ratio (TER) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+22.9%
+22.9%
+22.9%
+22.0%
+3.6%
3Y
+34.3%
+34.3%
+34.3%
+33.5%
NA
5Y
+30.0%
+30.0%
+30.0%
+28.6%
NA
ALL
+12.5%
+12.5%
+12.5%
+16.7%
+26.7%
VOL
20.0%
20.0%
20.0%
20.1%
14.1%
TER
0.8%
0.8%
0.8%
0.9%
0.9%
AUM
₹5,817 Cr
₹5,817 Cr
₹5,817 Cr
₹1,449 Cr
₹1,984 Cr
INFO
0.62
0.62
0.62
0.83
1.89
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
HDFC Pharma & Healthcare IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Dec
Top holdings
Sun Pharmaceuticals Industries Ltd
10.8%
Divi's Laboratories Ltd
8.3%
Glenmark Pharmaceuticals Ltd
6.5%
Lupin Ltd
6.0%
Alkem Laboratories Ltd
5.8%
Max Healthcare Institute Ltd Ordinary Shares
5.7%
Ipca Laboratories Ltd
4.6%
Anthem Biosciences Ltd
4.0%
Torrent Pharmaceuticals Ltd
3.9%
Aster DM Healthcare Ltd Ordinary Shares
3.3%
Top industry exposure
Healthcare
94.9%
Basic Materials
2.9%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹100
Additional lumpsum
₹100
Portfolio turnover
39%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
Fund manager(s)
Dhruv Muchhal
Nikhil Mathur

FAQs